Ionis Pharmaceuticals (IONS) PEG Ratio: History & Chart

Ionis Pharmaceuticals, Inc.(IONS)

Biotechnology · Carlsbad, CA

$44.13+0.63 (+1.46%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About Ionis Pharmaceuticals, Inc.

Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.

Carlsbad, CA

1,480 employees

www.ionis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Brett Monia

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Ionis Pharmaceuticals, Inc. (IONS)	$7.33B	N/A	N/A	N/A	N/A
Hinge Health, Inc. (HNGE)vs ›	$7.61B	N/A	N/A	N/A	N/A
Alkermes plc (ALKS)vs ›	$7.02B	N/A	N/A	N/A	N/A
HealthEquity, Inc. (HQY)vs ›	$7.66B	0.40	1.77	3.07	3.07
Cytokinetics, Incorporated (CYTK)vs ›	$7.65B	N/A	N/A	N/A	N/A
Praxis Precision Medicines, Inc. (PRAX)vs ›	$7.73B	N/A	N/A	N/A	N/A
Caris Life Sciences, Inc. (CAI)vs ›	$7.93B	N/A	N/A	N/A	N/A
Chemed Corporation (CHE)vs ›	$6.66B	N/A	2.98	2.74	2.10
Immunovant, Inc. (IMVT)vs ›	$6.60B	N/A	N/A	N/A	N/A
Hims & Hers Health, Inc. (HIMS)vs ›	$6.55B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Ionis Pharmaceuticals, Inc. (IONS)

$7.33B

N/A

Hinge Health, Inc. (HNGE)vs ›

$7.61B

N/A

Alkermes plc (ALKS)vs ›

$7.02B

N/A

HealthEquity, Inc. (HQY)vs ›

$7.66B

0.40

1.77

3.07

Cytokinetics, Incorporated (CYTK)vs ›

$7.65B

N/A

Praxis Precision Medicines, Inc. (PRAX)vs ›

$7.73B

N/A

Caris Life Sciences, Inc. (CAI)vs ›

$7.93B

N/A

Chemed Corporation (CHE)vs ›

$6.66B

N/A

2.98

2.74

2.10

Immunovant, Inc. (IMVT)vs ›

$6.60B

N/A

Hims & Hers Health, Inc. (HIMS)vs ›

$6.55B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

IONS PEG Ratio Metrics

IONS Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics